Promising Results for Dupilumab in Treatment of Moderate-to-Severe COPD with Type 2 Inflammation

This new data on dupilumab demonstrates the drug’s potential usefulness in treating type 2 inflammation, a role which is central to respiratory diseases including COPD.

Related Keywords

Milan ,Lombardia ,Italy ,Suryap Bhatt ,European Respiratory Society ,International Congress ,Critical Care ,Accessed September ,Copd ,Pulmonary ,Pulmonology ,Dupilumab ,Inflammation ,